Skip to content

The tolerability and pharmacokinetics of Qiangxin Fumai Granules on chinese healthy subjects

The tolerability and pharmacokinetics clinical trials of Qiangxin Fumai Granules on chinese healthy subjects

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900023863
Enrollment
Unknown
Registered
2019-06-15
Start date
2019-06-01
Completion date
Unknown
Last updated
2019-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bradyrhythmia

Interventions

Sponsors

Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Healthy subjects aged 18 to 50 years old, male and female equally. 2. Body mass index (BMI= weight/height 2) was between 19.0 and 25.0 (including the boundary value), and the weight of males was =50kg and females was =45kg. 3. Physical examination found no positive signs; 4. Have the ability to communicate with health care staff and comply with hospital regulations, understand and comply with research requirements; 5. Informed consent, volunteer subjects.

Exclusion criteria

Exclusion criteria: 1. Abnormal laboratory examination, imaging examination, electrocardiogram examination and physical examination with clinical significance; 2. A heavy smoker or alcoholic; 3. Substance abuser; 4. Participants who had participated in other clinical trials within three months prior to the trial and had been screened and enrolled; 5. Have used drugs known to cause damage to a certain organ or are currently using drugs within three months prior to the trial; 6. Those who donated blood or lost more than 400 ml of blood within three months before the test; 7. Any history of serious clinical diseases, such as respiratory system, circulatory system, digestive system, urogenital system, blood system, metabolic and endocrine system, motor system, neuropsychiatric system, musculoskeletal system, etc.; 8. Have a history of drug allergy or allergic constitution, and have allergies to the drug ingredients in the study; 9. Patients with medical history of heart, liver, kidney, digestive tract, breast, reproductive system (ovary, testis, epididymis, uterus) and neuropsychiatric system; 10. Immunological examination was positive; 11. Women who are pregnant or breast-feeding; Or have planned to have a family within the last six months or do not intend to take effective measures to prevent pregnancy during the study period; 12. Positive alcohol breath test (=5mg/100ml); 13. People who have used any food that affects the activity of liver medicine enzymes, or have used various drugs and health care products (including traditional Chinese medicine, self-made medicine wine, etc.) within 14 days before the test; 14. Symptoms: fever, heat aversion to cold, thirst, red face, restless, phlegm yellow and thick, short yellow urine, dry stool, red tongue and less fluid, moss yellow dryness, pulse number and other heat syndrome manifestations, referring to the above symptoms, by two senior title of Chinese doctors at the same time to determine, in line with the diagnostic criteria of TCM heat syndrome. 15. The investigator judged that the participants were not suitable for the clinical trial.

Design outcomes

Primary

MeasureTime frame
blood routine test;urine routine test;stool routine test;blood biochemistry test;ECG test;vital signs;Cmax;AUC0-t;24h DCG;Cmax,ss;Cmin,ss;Cav,ss;AUCss;

Secondary

MeasureTime frame
Tmax;T1/2;CL;Vd;?z;AUC0-t/AUC0-inf??;Residual area Ratio;Tmax,ss;

Countries

China

Contacts

Public ContactRui Gao

Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine

ruigao@126.com+86 13911097756

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026